Cargando…
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
The fetal tight junction molecule claudin 6 (CLDN6) is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need. We engineered 6PHU3, a T-cell-engaging bispecific single chain molecule (bi-(scFv)(2)) with anti-CD3/anti-CLDN6 s...
Autores principales: | Stadler, Christiane R., Bähr-Mahmud, Hayat, Plum, Laura M., Schmoldt, Kathrin, Kölsch, Anne C., Türeci, Özlem, Sahin, Ugur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839326/ https://www.ncbi.nlm.nih.gov/pubmed/27141353 http://dx.doi.org/10.1080/2162402X.2015.1091555 |
Ejemplares similares
-
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023) -
Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice
por: Skeltved, Nanna, et al.
Publicado: (2023) -
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019) -
Targeting the tumor vasculature with engineered cystine-knot miniproteins
por: Lui, Bonny Gaby, et al.
Publicado: (2020) -
Tenascin and oncofetal fibronectin--oncofetal markers or indicators of extracellular matrix remodelling?
por: David, L.
Publicado: (1996)